Clinical Trial Update: Gene Therapy for Achromatopsia (CNGB3) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of gene therapy for achromatopsia (CNGB3) completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achromatopsia

Drugs mentioned

• Gene therapy for CNGB3-associated achromatopsia

Snippet

Sponsor: MeiraGTx UK II Ltd | Conditions: Achromatopsia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-08